Safety signal of CIDP with use of AstraZeneca COVID-19 vaccine

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1974卷 / 1期

关键词：

D O I：

10.1007/s40278-023-46017-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：6 / 6

相关论文

共 50 条

[1] Long-term safety of AstraZeneca COVID-19 vaccine
Reactions Weekly, 2023, 1956 (1) : 10 - 10
[2] AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Reactions Weekly, 2021, 1851 (1) : 1 - 2
[3] Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca
Reactions Weekly, 2021, 1857 (1) : 4 - 4
[4] Acute rejection following COVID-19 vaccine (AstraZeneca)
Varma, Prem P.
Kute, Vivek B.
Kumar, Prateek
INDIAN JOURNAL OF TRANSPLANTATION, 2022, 16 (04) : 465 - 466
[5] Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Reactions Weekly, 2021, 1853 (1) : 1 - 1
[6] TTS rare after AstraZeneca COVID-19 vaccine
Reactions Weekly, 2022, 1923 (1) : 12 - 12
[7] Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
Agharbi, F. -Z
Eljazouly, M.
Basri, G.
Faik, M.
Benkirane, A.
Albouzidi, A.
Chiheb, S.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2022, 149 (01): : 56 - 57
[8] Bleeding and clotting with AstraZeneca's COVID-19 vaccine
Reactions Weekly, 2021, 1857 (1) : 1 - 1
[9] No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Reactions Weekly, 2021, 1849 (1) : 3 - 3
[10] Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Reactions Weekly, 2021, 1848 (1) : 1 - 1

← 1 2 3 4 5 →